文献速递骨质疏松与代谢性骨病骨肿瘤

骨密度筛查对接受芳香化酶抑制剂治疗绝经后乳腺癌幸存者新发骨折及医疗资源利用的影响

The impact of bone mineral density screening on incident fractures and healthcare resource utilization among postmenopausal breast cancer survivors treated with aromatase inhibitors.
PubMed 文献 · Osteoporos Int · 2022-06-14

该回顾性队列研究基于Medicare关联的SEER数据库分析22,713例接受芳香化酶抑制剂治疗的0-III期原发性乳腺癌幸存者,62%接受了DXA筛查。经倾向性评分校正后,接受DXA筛查者任何骨折风险降低32%(HR 0.68,95%CI 0.60-0.76,p<0.001),住院(HR 0.73,95%CI 0.62-0.86)和门诊服务使用(HR 0.85,95%CI 0.74-0.97)也更低。作者结论认为骨密度筛查与骨折及医疗资源利用减少相关,接受AI治疗的绝经后乳腺癌幸存者应进行适当的骨密度筛查。

要点

  • 接受DXA筛查者任何骨折风险较未筛查者降低32%(HR 0.68,95%CI 0.60-0.76,p<0.001)。
  • 接受DXA筛查者住院可能性更低(HR 0.73,95%CI 0.62-0.86),门诊服务使用也更低(HR 0.85,95%CI 0.74-0.97)。
  • 作者结论认为接受AI治疗的绝经后乳腺癌幸存者应进行适当的骨密度筛查。

核心结论

  • 骨密度筛查与接受芳香化酶抑制剂治疗的绝经后乳腺癌幸存者新发骨折减少及骨折相关事件医疗资源利用可能性降低相关。
  • 作者结论认为接受AI治疗的绝经后乳腺癌幸存者应进行适当的骨密度筛查,以降低发病率、死亡率和医疗费用。

研究设计与样本

  • 回顾性分析Medicare关联的监测、流行病学和最终结果(SEER)数据库中22,713例0-III期原发性乳腺癌幸存者,均在乳腺癌诊断前≤1年内接受芳香化酶抑制剂治疗。
  • DXA筛查定义为首次AI索赔前12个月至后6个月内有操作索赔记录,采用倾向性评分方法评估DXA筛查与骨折及医疗资源利用的关联。

主要发现

  • 研究队列中62%接受了DXA筛查。
  • 合并痴呆、肾脏疾病和充血性心力衰竭的女性接受DXA的可能性更低。
  • 校正混杂因素后,接受DXA的乳腺癌幸存者任何骨折风险较未接受者降低32%(HR 0.68,95%CI 0.60-0.76,p<0.001)。
  • 接受DXA者住院可能性更低(HR 0.73,95%CI 0.62-0.86),使用门诊服务的可能性也更低(HR 0.85,95%CI 0.74-0.97)。

临床怎么用

  • 作者结论认为接受AI治疗的绝经后乳腺癌幸存者应进行适当的骨密度筛查,以降低发病率、死亡率和医疗费用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Bone mineral density screening prior to initiating aromatase inhibitor therapy was associated with lower incident bone fractures and healthcare resource utilization among postmenopausal breast cancer survivors. INTRODUCTION: Postmenopausal women with hormone receptor-positive breast cancer (BC) often receive aromatase inhibitor (AI) therapy. However, AIs induce bone loss and BC survivors are at an increased risk of bone fractures. This study determined whether receipt of baseline dual-energy x-ray absorptiometry (DXA) screening is associated with decreased incident fractures and lower healthcare resource utilization. METHODS: We retrospectively analyzed 22,713 stage 0-III primary BC survivors who received AI therapy ≤ 1 year prior to BC diagnosis from the Medicare-Linked Surveillance, Epidemiology, and End-Results database. We categorized DXA screening for those who had a procedural claim within 12 months prior through 6 months after first AI claim. We used propensity score methods to assess the association of DXA screening with bone fractures and health resource utilization. RESULTS: Of the study cohort, 62% received a DXA screening. Women with comorbid dementia, renal disease, and congestive heart failure were less likely to receive a DXA. After adjusting for confounders, BC survivors who received a DXA had a 32% decreased risk of any bone fracture compared to those who did not (hazard ratio (HR): 0.68, 95% confidence interval (CI): 0.60-0.76, p < 0.001). Similarly, those who received a DXA were less likely to be hospitalized (HR 0.73 (0.62-0.86)) or use outpatient services (HR 0.85 (0.74-0.97)). CONCLUSIONS: Bone density screening is associated with decreased incident bone fractures and a lower likelihood of utilizing healthcare resource for fracture-related events. Postmenopausal BC survivors treated with AIs should undergo appropriate bone density screening to reduce morbidity, mortality, and health care expenses.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Bailey S, Mhango G, Lin JJ, et al. The impact of bone mineral density screening on incident fractures and healthcare resource utilization among postmenopausal breast cancer survivors treated with aromatase inhibitors. Osteoporos Int. 2022. PMID: 35697870. doi:10.1007/s00198-022-06458-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。